GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Know Labs Inc.
Kronos Bio is a biotech company specializing in cancer treatments by targeting transcription factors. Its stock price is highly volatile and depends on the results of clinical trials of its innovative but complex scientific platform.
Share prices of companies in the market segment - Therapeutic medical equipment
Know Labs is developing a non-invasive technology for monitoring blood glucose levels using radiofrequency sensors. We've classified it as "Therapeutic Medical Equipment." The chart below shows how investors value companies working on breakthroughs in diabetes diagnostics.
Broad Market Index - GURU.Markets
Know Labs is a company developing a non-invasive technology for measuring blood glucose levels using radiofrequency waves. As a pioneer, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with Know Labs' performance to assess the state of this sector.
Change in the price of a company, segment, and market as a whole per day
KNW - Daily change in the company's share price Know Labs Inc.
The daily price change of Know Labs, Inc., a developer of a non-invasive glucometer, reflects the high volatility of the MedTech sector. The indicator demonstrates sensitivity to news about clinical trials and technological breakthroughs.
Daily change in the price of a set of shares in a market segment - Therapeutic medical equipment
Know Labs is developing a non-invasive technology for monitoring blood glucose levels using radiofrequency. This is a potentially revolutionary technology in medicine. The chart below shows the volatility in the medical device sector, reflecting the enormous expectations and risks associated with KNW's developments.
Daily change in the price of a broad market stock, index - GURU.Markets
Know Labs is developing a non-invasive technology for monitoring blood glucose levels. This innovative medical technology company's stock reflects the hopes of millions of people for a more convenient way to manage diabetes. Its high volatility stems from both the risks and the prospects.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Know Labs Inc.
Know Labs, Inc.'s annual performance is the story of its noninvasive glucometer development. Its 12-month market cap depends entirely on progress in the development and testing of its device, which uses radiofrequency technology. A successful demonstration of accuracy will be a fundamental breakthrough for millions of diabetics.
Annual dynamics of market capitalization of the market segment - Therapeutic medical equipment
Know Labs develops non-invasive glucose monitoring technology. Its stock price is entirely speculative and based on investors' belief in its ability to commercialize its revolutionary technology, rather than current financial results, making it unique in the sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Know Labs, a company developing non-invasive blood glucose monitoring technology, aims to revolutionize diabetes treatment. Its year-over-year market capitalization trend reflects the company's hopes for a technological breakthrough. The success of its device could change the lives of millions and create enormous value.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Know Labs Inc.
Know Labs is developing a noninvasive glucose monitoring technology. While it's still in development, its monthly evaluation is based solely on expectations. News about technological progress and interactions with the FDA are the primary drivers.
Monthly dynamics of market capitalization of the market segment - Therapeutic medical equipment
This chart reflects the dynamics of the nascent non-invasive diagnostics sector. For Know Labs, one of the pioneers, it's the backdrop. Its volatile movements reflect not current revenue, but investor expectations related to progress in this complex and promising technology.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Know Labs is developing a non-invasive glucose monitoring technology using radio waves. It's a potentially revolutionary product. The company's success depends entirely on the accuracy and approval of its device. The overall market chart provides only background; Know Labs shares are driven by news of technological breakthroughs, and their volatility can be extreme.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Know Labs Inc.
Know Labs is developing a non-invasive blood glucose monitoring technology. Its weekly stock price is highly speculative and depends on news about progress in the development and testing of this potentially revolutionary technology.
Weekly dynamics of market capitalization of the market segment - Therapeutic medical equipment
Know Labs is developing a non-invasive blood glucose monitoring technology. It's the "holy grail" for diabetics. The chart will show whether the company's stock price fluctuations are a reaction to news about its technology and clinical trials or whether they reflect general investor sentiment in the field of breakthrough medical devices.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Know Labs is working on the "holy grail" of diabetes treatment—a non-invasive glucometer. Success would be revolutionary, but the risk of failure is enormous. The stocks of venture-backed companies like these are driven not by earnings reports, but by news of technological breakthroughs and trial data. This chart clearly demonstrates its speculative nature and extreme volatility.
Market capitalization of the company, segment and market as a whole
KNW - Market capitalization of the company Know Labs Inc.
Know Labs' market capitalization is a highly speculative bet on its breakthrough non-invasive blood glucose monitoring technology. Its volatile price reflects both the enormous potential of this "Holy Grail" diabetes treatment and the immense skepticism about whether its technology can actually work.
KNW - Share of the company's market capitalization Know Labs Inc. within the market segment - Therapeutic medical equipment
Know Labs is developing a non-invasive blood glucose monitoring technology. Its market share in the medical device sector is currently zero, as the product is still in development. Its market cap is a clear bet on a technological breakthrough that could revolutionize the multi-billion dollar diabetes treatment market.
Market capitalization of the market segment - Therapeutic medical equipment
Here's a chart showing the market capitalization of the medical diagnostics sector. Know Labs is a futuristic company developing a non-invasive glucometer based on radio waves. The potential for this market is enormous, as it's the "holy grail" for millions of diabetics. Know Labs' performance represents an extremely risky bet on the success of its revolutionary technology.
Market capitalization of all companies included in a broad market index - GURU.Markets
Know Labs is developing a non-invasive technology for measuring blood glucose levels using radiofrequency. Its speculative market cap is a bet on a breakthrough in diabetes treatment. The chart below shows the economic weight of companies solving this huge medical problem.
Book value capitalization of the company, segment and market as a whole
KNW - Book value capitalization of the company Know Labs Inc.
Know Labs's book value is derived from its intellectual property rights to its unique technology for noninvasive blood glucose monitoring using radio waves. The chart tells the story of a company that has invested decades in developing this breakthrough technology, building its intangible foundation in hopes of revolutionizing diabetes treatment.
KNW - Share of the company's book capitalization Know Labs Inc. within the market segment - Therapeutic medical equipment
Know Labs is developing a non-invasive glucometer. The chart shows its share of actual R&D assets. These are its laboratories, where, using unique radiofrequency technology, they are creating the sensor, which is their main material innovation.
Market segment balance sheet capitalization - Therapeutic medical equipment
Know Labs is developing a non-invasive blood glucose monitoring technology. Their business is focused on R&D and intellectual property, not mass production. The book value chart shows the value of their laboratories, which is merely the foundation for future technologies.
Book value of all companies included in the broad market index - GURU.Markets
Know Labs' assets include laboratories and equipment for developing a noninvasive glucometer based on their patented radiofrequency technology. The chart below shows how the company is building the material foundation for this breakthrough device.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Know Labs Inc.
Know Labs develops non-invasive glucose monitoring sensors. Its value lies in its revolutionary technology. The chart below is a pure bet on a medical breakthrough. The market cap reflects the company's hopes of creating the "Holy Grail" for diabetics and has nothing to do with its current assets.
Market to book capitalization ratio in a market segment - Therapeutic medical equipment
Know Labs is developing a non-invasive technology for monitoring blood glucose levels using radio waves. It's a development-stage company. Its valuation is based on the enormous potential of this technology, which could revolutionize diabetes treatment. The graph reflects the high risk and high expectations.
Market to book capitalization ratio for the market as a whole
Know Labs develops non-invasive medical sensors, such as those for measuring glucose levels. The company's value lies in its breakthrough technology and patents. This chart shows that investors are not evaluating current assets, but rather the enormous potential of its technology to change the lives of millions of people, which creates a high premium to its book value.
Debts of the company, segment and market as a whole
KNW - Company debts Know Labs Inc.
Know Labs is developing a non-invasive technology for monitoring blood glucose levels using radio waves. This chart shows the company's financial status at the R&D stage. It has no revenue and funds its long-term and risky research exclusively through equity capital.
Market segment debts - Therapeutic medical equipment
Know Labs is developing a non-invasive blood glucose monitoring technology. It's the "holy grail" for diabetics, and many companies have failed. This chart shows the company's financial status during the R&D phase, when it's trying to prove the viability of its breakthrough, but highly risky, technology.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Know Labs Inc.
Know Labs is developing a non-invasive glucose monitoring technology. This chart shows the innovative company's financial structure. Debt at a stage before regulatory approval and commercialization of the technology is a huge risk.
Market segment debt to market segment book capitalization - Therapeutic medical equipment
Know Labs is developing a non-invasive blood glucose monitoring technology. This chart shows the debt burden in the therapeutic medical device sector. For companies developing breakthrough technologies, it is a critical indicator of their ability to finance their long-term and risky research.
Debt to book value of all companies in the market
Know Labs is developing a non-invasive blood glucose monitoring technology. It's a "holy grail" for diabetics, but it's a technologically challenging task. This chart of total market debt shows how willing the financial world is to finance such long-term, high-risk, but potentially revolutionary medical projects.
P/E of the company, segment and market as a whole
P/E - Know Labs Inc.
Know Labs is developing a non-invasive technology for monitoring blood glucose levels using radiofrequency waves. This chart reflects the enormous, yet highly speculative, investor expectations for this potential "Holy Grail" in diabetes treatment. Its growth depends entirely on the successful validation and commercialization of this technology.
P/E of the market segment - Therapeutic medical equipment
Know Labs is developing a non-invasive technology for monitoring blood glucose levels using radiofrequency waves. This could be a breakthrough for millions of people with diabetes, eliminating the need for needlesticks. This chart shows the average valuation for the therapeutic devices sector, reflecting investor hopes for revolutionary diagnostic technologies.
P/E of the market as a whole
Know Labs is developing a non-invasive radiofrequency-based blood glucose monitoring technology. Its valuation is a pure bet on this revolutionary technology. It is not tied to the general economic cycles reflected here, but depends entirely on the success of its developments and regulatory approval.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Know Labs Inc.
Know Labs is a company developing a non-invasive technology for measuring blood glucose levels using radiofrequency waves. This chart reflects investors' confidence in the revolutionary potential of this device. Future profits are entirely dependent on the success of clinical trials and regulatory approval.
%20P%2FE%20Know%20Labs%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Know-Labs-Inc.&v=1772644393594 "Chart of the company's future (projected) P/E Know Labs Inc.")
Future (projected) P/E of the market segment - Therapeutic medical equipment
Know Labs is developing a non-invasive technology for monitoring blood glucose levels using radiofrequency spectroscopy. This chart shows general expectations for the medical device sector. KNW's position relative to the average reflects whether investors believe their revolutionary technology will successfully pass clinical trials and transform the lives of diabetics.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Therapeutic%20medical%20equipment&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Therapeutic-medical-equipment&v=1772644393613 "Future (projected) P/E graph of the market segment - Therapeutic medical equipment")
Future (projected) P/E of the market as a whole
Know Labs is developing a non-invasive technology for monitoring blood glucose levels using radiofrequency spectroscopy. The goal is to create a wearable device that will replace traditional finger-prick glucose meters. This chart of overall market expectations shows how willing investors are to invest in breakthrough but high-risk medical technologies.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772644393625 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Know Labs Inc.
Know Labs, Inc. is developing a non-invasive technology for monitoring blood glucose levels using radiofrequency sensors. Its financial schedule is based on significant R&D expenditures. The company's potential is enormous, but it depends entirely on the success and approval of this breakthrough technology.
Profit of companies in the market segment - Therapeutic medical equipment
Know Labs is developing a non-invasive technology for monitoring blood glucose levels using radiofrequency spectroscopy. This is a potentially breakthrough technology for diabetics. This chart shows the collective revenue of therapeutic device manufacturers, demonstrating the enormous commercial potential for breakthrough non-invasive diagnostic devices.
Overall market profit
Know Labs is developing a non-invasive technology for monitoring blood glucose levels using radio waves. This is a potentially revolutionary technology for diabetics. The company's success depends on the technology's accuracy and regulatory approval. The overall economic backdrop, shown in this chart, is important for attracting significant investment in R&D.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Know Labs Inc.
Know Labs is developing a non-invasive blood glucose monitoring technology using radiofrequency spectroscopy. Future profits depend on the success of this breakthrough technology. This chart reflects analysts' speculative expectations regarding the commercial potential of this "Holy Grail" in diabetes treatment.
%20profit%20of%20the%20company%20Know%20Labs%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Know-Labs-Inc.&v=1772644393646 "Graph of future (projected) profit of the company Know Labs Inc.")
Future (predicted) profit of companies in the market segment - Therapeutic medical equipment
Know Labs is developing a non-invasive technology for monitoring blood glucose levels using radiofrequency waves. This technology could revolutionize diabetes treatment by eliminating the need for finger pricks. This chart shows forecasts for the medical device sector, helping to appreciate the enormous, yet risky, potential of Know Labs' breakthrough technology.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Therapeutic%20medical%20equipment&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Therapeutic-medical-equipment&v=1772644393647 "Graph of future (predicted) profits of companies in a market segment - Therapeutic medical equipment")
Future (predicted) profit of the market as a whole
Know Labs, Inc. develops noninvasive blood glucose monitoring technologies. As a company in the R&D stage, its success is entirely dependent on technological breakthroughs and regulatory approval. The macroeconomic indicators shown in this chart are not relevant for assessing its potential.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772644393648 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Know Labs Inc.
Know Labs is developing a non-invasive blood glucose monitoring technology. In the absence of a commercial product, its valuation, as shown in this chart, is a pure bet on a technological breakthrough. The trend reflects investors' belief that the company will be able to create the "holy grail" for diabetics and successfully commercialize it.
P/S market segment - Therapeutic medical equipment
Know Labs is developing a non-invasive radiofrequency-based blood glucose monitoring technology. Future revenue depends on the success and commercialization of this technology. This chart for the medical device sector reflects the high investor expectations for the potential breakthrough in diabetes treatment that Know Labs may offer.
P/S of the market as a whole
Know Labs is developing a non-invasive technology for monitoring blood glucose levels using radiofrequency waves. This market revenue valuation chart helps illustrate the enormous expectations investors have for this potential breakthrough, which could change the lives of millions of people with diabetes.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Know Labs Inc.
Know Labs is developing a non-invasive technology for blood glucose monitoring using radiofrequency sensors. This chart illustrates the market's perception of the future commercial potential of this revolutionary technology. It reflects the company's belief that it can create a convenient alternative to traditional glucose measurement methods.
%20P%2FS%20Know%20Labs%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Know-Labs-Inc.&v=1772644393660 "The graph of the company's future (projected) P/S Know Labs Inc.")
Future (projected) P/S of the market segment - Therapeutic medical equipment
Know Labs is developing a non-invasive blood glucose monitoring technology using radiofrequency. The company's valuation is highly speculative and reflects high hopes that it will create the "holy grail" for diabetics. However, it carries enormous technological and regulatory risks, as many previous attempts have failed.
%20P%2FS%20market%20segment%20graph%20-%20Therapeutic%20medical%20equipment&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Therapeutic-medical-equipment&v=1772644393670 "Future (projected) P/S market segment graph - Therapeutic medical equipment")
Future (projected) P/S of the market as a whole
Know Labs, Inc. is developing a non-invasive technology for monitoring blood glucose levels using radio waves. This is a potentially revolutionary product for diabetics. Revenue growth projections reflected here are subject to change if such innovations change healthcare standards.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772644393670 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Know Labs Inc.
Know Labs is developing a non-invasive technology for blood glucose monitoring using radiofrequency. Being in the research and development phase, the company does not yet have a commercial product and, therefore, does not generate sales revenue.
Sales of companies in the market segment - Therapeutic medical equipment
Know Labs (KNW) is developing a non-invasive technology for monitoring blood glucose levels using radiofrequency sensors. This figure reflects the revenue of the therapeutic equipment market. If successful, Know Labs' technology could revolutionize diabetes treatment, eliminating the need for finger pricks.
Overall market sales
Know Labs is developing a non-invasive technology for monitoring blood glucose levels. Its success depends on the technology's accuracy and regulatory approval. This pattern of overall economic activity affects the availability of capital for long-term R&D projects. During periods of growth, investors are more willing to invest in breakthrough medical technologies with a huge potential market.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Know Labs Inc.
Know Labs is developing a non-invasive technology for monitoring blood glucose levels using radiofrequency sensors. The company's future revenue depends on the successful commercialization and regulatory approval of this breakthrough technology. This chart reflects analysts' forecasts, which are essentially a bet on their device revolutionizing diabetes treatment.
%20sales%20of%20the%20company%20Know%20Labs%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Know-Labs-Inc.&v=1772644393678 "Schedule of future (projected) sales of the company Know Labs Inc.")
Future (projected) sales of companies in the market segment - Therapeutic medical equipment
Know Labs is developing a non-invasive technology for monitoring blood glucose levels using radiofrequency. This forecast chart shows the potential future revenue from their devices after approval. This is analysts' perspective on the commercial prospects of this breakthrough technology for millions of people with diabetes.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Therapeutic%20medical%20equipment&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Therapeutic-medical-equipment&v=1772644393679 "Schedule of future (projected) sales of companies in the market segment - Therapeutic medical equipment")
Future (projected) sales of the market as a whole
Know Labs is developing a non-invasive technology for measuring blood glucose levels using radio waves. This could revolutionize the lives of millions of diabetics. This chart illustrates general trends in medical technology, but for Know Labs, proving the accuracy and reliability of its technology is key, as it could completely transform the diabetes monitoring device market.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772644393683 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Know Labs Inc.
Know Labs, Inc. is developing a non-invasive technology for monitoring blood glucose levels using radiofrequency waves. While in the R&D phase, the company incurs significant expenses. The chart shows the financial trajectory of the innovative company, whose future profitability depends on the success of this potentially revolutionary medical technology.
Market segment marginality - Therapeutic medical equipment
Know Labs is developing a non-invasive technology for blood glucose monitoring using radiofrequency waves. This chart reflects its operating expenses during the R&D phase. Future profitability is entirely dependent on the successful development and commercialization of this potentially breakthrough medical device.
Market marginality as a whole
Know Labs is developing a non-invasive blood glucose monitoring technology. This is a potentially breakthrough technology for millions of people with diabetes. This gross profit chart reflects the market's willingness to fund such ambitious projects. Economic growth and investor optimism are necessary to bring such complex technologies to market.
Employees in the company, segment and market as a whole
Number of employees in the company Know Labs Inc.
Know Labs is developing a breakthrough technology for non-invasive blood glucose monitoring using radiofrequency sensors. This graphic shows the team of scientists and engineers working on a device that could change the lives of millions of people with diabetes by eliminating the need for finger pricking.
Share of the company's employees Know Labs Inc. within the market segment - Therapeutic medical equipment
Know Labs is developing a non-invasive technology for monitoring blood glucose levels using radio waves. During the development phase of such a revolutionary technology, its most important asset is its team of scientists and engineers. This chart shows the company's investment in intellectual capital to create this "holy grail" for diabetics, a measure of its scientific potential.
Number of employees in the market segment - Therapeutic medical equipment
Know Labs, Inc. is developing a non-invasive radiofrequency blood glucose monitoring technology. This chart, which shows employment in the therapeutic medical device sector, demonstrates the huge demand for the best diabetes solutions. For Know Labs, if their technology is successful, it will revolutionize a multi-billion dollar market.
Number of employees in the market as a whole
Know Labs is developing a non-invasive technology for monitoring blood glucose levels. This is a potentially revolutionary device for diabetics. The implementation of such advanced medical technologies depends on investment and the ability of the healthcare system to pay. The growth in overall employment shown in this chart supports this system, making breakthrough innovations possible.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Know Labs Inc. (KNW)
Know Labs (KNW) is developing a non-invasive glucose monitoring technology (Bio-RFID). It's an R&D-intensive MedTech. This chart reflects the market value of their patents and the potential for a "holy grail" in diabetes treatment. Value is created by the R&D team, not production, which translates into high employee valuations.
%20of%20the%20company%20Know%20Labs%20Inc.%20(KNW)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Know-Labs-Inc.-KNW&v=1772644393705 "Chart of market capitalization per employee (in thousands of dollars) of the company Know Labs Inc. (KNW)")
Market capitalization per employee (in thousands of dollars) in the market segment - Therapeutic medical equipment
Know Labs is developing a non-invasive blood glucose monitoring technology. In the MedTech industry, early-stage market cap reflects the potential of a revolutionary technology. This metric demonstrates the enormous future value the market places on its ability to change the lives of millions of diabetics.
%20by%20market%20segment%20-%20Therapeutic%20medical%20equipment&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Therapeutic-medical-equipment&v=1772644393706 "Market capitalization per employee (in thousands of dollars) by market segment - Therapeutic medical equipment")
Market capitalization per employee (in thousands of dollars) for the overall market
Know Labs is developing a non-invasive technology for measuring blood glucose levels using radio waves. This is a breakthrough medical technology. This chart for Know Labs shows how the MedTech sector's per-employee market cap can be astronomical, based on the technology's potential to completely transform the lives of hundreds of millions of diabetics.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772644393706 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Know Labs Inc. (KNW)
Know Labs is an R&D company trying to create a non-invasive glucometer, the "holy grail" of diabetes treatment. The company has no product and no profit. This graph shows a negative value—the investment (loss) per engineer. This reflects the high cost of R&D in an attempt to achieve a technological breakthrough.
%20Chart%20Know%20Labs%20Inc.%20(KNW)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Know-Labs-Inc.-KNW&v=1772644393715 "Company Profit Per Employee (in thousands of dollars) Chart Know Labs Inc. (KNW)")
Profit per employee (in thousands of dollars) in the market segment - Therapeutic medical equipment
Know Labs, Inc. is developing a non-invasive technology for monitoring blood glucose levels using radio waves. In the field of game-changing medical technologies, the effectiveness of a small team of scientists and engineers determines the future. This metric reflects the potential value each employee can create if a breakthrough technology is successful.
%20in%20the%20market%20segment%20-%20Therapeutic%20medical%20equipment&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Therapeutic-medical-equipment&v=1772644393716 "Chart of profit per employee (in thousands of dollars) in the market segment - Therapeutic medical equipment")
Profit per employee (in thousands of dollars) for the market as a whole
Know Labs is developing a non-invasive technology (Bio-RFID) for monitoring blood glucose levels. Their goal is to create a "puncture-free glucometer." This is R&D in medtech. This graph shows the average profitability per employee across the economy. It helps investors understand the potential of the medtech sector, where patents and R&D are crucial, to generate high added value.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772644393719 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Know Labs Inc. (KNW)
Know Labs is developing a non-invasive technology for monitoring blood glucose levels using radiofrequency. While the company is in the development and approval stages, it has no commercial revenue yet. The chart will show zero, emphasizing that its value lies in the potential of its breakthrough technology, which could change the lives of millions of diabetics.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Know-Labs-Inc.-KNW&v=1772644393720 "Sales chart per company employee Know Labs Inc. (KNW)")
Sales per employee in the market segment - Therapeutic medical equipment
Know Labs (KNW) develops non-invasive diagnostic technologies, specifically the Bio-RFID sensor for non-invasive blood glucose measurement. This chart shows the average revenue per employee in this segment. For a company in the R&D stage, this is important for assessing the efficiency of capital and personnel utilization compared to competitors.
Sales per employee for the market as a whole
Know Labs (KNW) is a technology company developing a non-invasive technology (Bio-RFID) for blood glucose monitoring. This is a potentially revolutionary device for diabetics. The company has no revenue. This zero figure reflects the investment in the team of engineers and scientists working on this complex R&D project.
Short shares by company, segment and market as a whole
Shares shorted by company Know Labs Inc. (KNW)
Know Labs (KNW) is a micro-cap company that claims to be developing a non-invasive glucose monitor (using radio waves). This is the "holy grail" of diabetes treatment. This chart shows short interest. The high bearish rates reflect deep investor skepticism about this technology (which giants have unsuccessfully tried to develop) and the lack of a working prototype. (349)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Know-Labs-Inc.-KNW&v=1772644393723 "Short Shares Chart for the Company Know Labs Inc. (KNW)")
Shares shorted by market segment - Therapeutic medical equipment
Know Labs (KNW) is developing a non-invasive technology (Bio-RFID) for blood glucose monitoring. It's the "holy grail" for diabetics. The chart below shows the overall short position in the medical equipment sector. It shows how skeptical investors are about the success of this complex technology.
Shares shorted by the overall market
Know Labs (KNW) is an R&D company developing a non-invasive glucometer. It's a speculative bet on the "technology of the future." When this market fear indicator rises, investors are unwilling to fund "science." They're selling off "concept stocks" en masse without profit, fearing KNW will run out of cash before it hits the market.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Know Labs Inc. (KNW)
This oscillator for Know Labs is pure speculative hype. The company promises the "holy grail"—a non-invasive glucometer (Bio-RFID). Any press release about a "breakthrough" or "successful test" causes wild "overheating" (above 70). The lack of a commercial product, skepticism from the scientific community, and constant delays keep the shares "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Know-Labs-Inc.-KNW&v=1772644393736 "RSI 14 indicator chart for the company's stock Know Labs Inc. (KNW)")
RSI 14 Market Segment - Therapeutic medical equipment
Know Labs (KNW) is chasing the "Holy Grail" of diabetes—a non-invasive glucometer. It's one of the most speculative stories in medtech. This chart shows the collective hype and fear in the Medical Devices sector. It helps investors understand whether the entire sector is overheated by hopes for breakthroughs or oversold, which is the backdrop for assessing KNW's risk.
RSI 14 for the overall market
For Know Labs, an R&D company, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to generously fund risky but promising "technologies of the future." During periods of panic, the money supply is turned off, and companies burning through cash risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast KNW (Know Labs Inc.)
Know Labs is developing a non-invasive technology (Bio-RFID) for glucose monitoring. Their goal is to create a wearable device that measures blood sugar without pricking a finger. This chart shows the speculative average 12-month price target from analysts, which is based entirely on their belief in this technology and FDA approval.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-KNW-Know-Labs-Inc.&v=1772644393744 "A chart showing analyst consensus forecasts for the expected stock price. KNW (Know Labs Inc.)")
The difference between the consensus estimate and the actual stock price KNW (Know Labs Inc.)
Know Labs (KNW) is betting on the "Holy Grail" of diabetes. The company is developing a non-invasive glucometer (Bio-RFID) that could change the lives of millions. This chart shows how far the current stock price differs from its "fair" value. The gap reflects analysts' faith (or skepticism) in this breakthrough, yet unproven, technology.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-KNW-Know-Labs-Inc.&v=1772644393745 "A chart showing the difference between the consensus forecast and the actual stock price. KNW (Know Labs Inc.)")
Analyst consensus forecast for stock prices by market segment - Therapeutic medical equipment
Know Labs (KNW) is a pure R&D bet on the "holy grail" of diagnostics: a noninvasive glucose monitor. The company is developing a Bio-RFID sensor for measuring blood sugar without needles. This chart reflects the collective opinion of the *entire* therapeutic/diagnostic equipment sector. It shows whether experts believe in the viability of this "moonshot" technology.
Analysts' consensus forecast for the overall market share price
Know Labs (KNW) is a company working on the "holy grail" of diagnostics: non-invasive glucose monitoring (no need to puncture a blood sample). They are developing Bio-RFID technology. This chart shows the overall "risk appetite" in the market. For KNW, a development-stage company whose value is pure expectation, overall market optimism (an upward trend in the chart) is critical for funding R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Know Labs Inc.
Know Labs (KNW) is an R&D company working on the Holy Grail of diabetes: a non-invasive glucose monitor. Their signature technology is Bio-RFID, which (in theory) measures blood sugar through the skin without piercing. This chart is a pure R&D barometer of faith/fear. It reflects not sales, but the market's speculative valuation of their (very risky) R&D progress.
AKIMA Market Segment Index - Therapeutic medical equipment
Know Labs (KNW) is developing the Holy Grail of diabetes—a noninvasive glucometer. Their Bio-RFID therapeutic technology is designed to measure blood sugar using radio waves, without pricking a finger. This graph compares their composite index to the sector, showing how far their noninvasive technology is ahead of the competition.
The AKIM Index for the overall market
Know Labs (KNW) is a company developing non-invasive medical diagnostics, including glucose monitoring using radio waves. This chart, which reflects the market average, is the backdrop. It helps assess how this speculative early-stage tech story fits into the overall macroeconomic picture.
